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Abstract
Objective: The objective of this selective EBM review is to determine whether or not
belatacept improves patient/graft survival after 1 year versus calcineurin inhibitors based
regimens.
Study Design: Review of one randomized controlled trial published in 2010 and two
randomized controlled trials published in 2011 were used for this review and selected
based on their relevance to the clinical question.
Data Sources: Studies were found using PubMed, and Medline Plus.
Outcomes Measured: All three studies measured patient/graft survival after 12 months
as either a primary or secondary outcome.
Results: Vincenti et al (2010) showed belatacept to have a 97% patient/graft survival
after 12 months, cyclosporine with 93% patient/graft survival rate. Adverse events
(tremors) in this study where noted at 5% for belatacept and 16% for cyclosporine. In
Rostaing et al (2011) RCT patient/graft survival was shown as 100% with belatacept and
99% with cyclosporine. Adverse events (pyrexia and pyelonephritis) where calculated to
be 20% for belatacept and 19% for cyclosporine. In Rostaing et al (2011) post hoc
analysis patient graft survival rates for belatacept where 92.8% and cyclosporine 80.8%.
Adverse events in this study where 54.6% for belatacept and 67.2% for cyclosporine.
Conclusion: The results of these three RCT are inconclusive as to the efficacy of
belatacept over cyclosporine in regards to patient/graft survival after 12 months.
Key words: belatacept, calcineurin inhibitors, kidney, renal function
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Introduction	
  
Chronic kidney disease affects millions of people worldwide. Lack of affordable
healthcare treatment options leads to death for many of these patients.1 Millions of
patients are receiving treatment either from dialysis or a kidney transplant in effort to stay
alive. Even though millions are receiving these live saving treatment options there are
still many more patients going without treatment for one reason or another. 2
According to the World Health Organization “in the year 2005, there were
approximately 58 million deaths worldwide, with 35 million attributed to chronic
disease.” 3 Even after receiving a life saving kidney transplant there are still obstacles that
a patient faces to maintain the transplanted organ. Two common causes of death or
transplant failure in renal transplant patients include cardiovascular disease and chronic
allograft nephropathy. 2
“There are currently 119,825 people waiting for lifesaving organ transplants in
the U.S. of these, 99,261 await kidney transplants.” 4 The cost of kidney disease is
straining the US healthcare system. It is estimated that the cost for one year of medical
expenses in addition to the kidney transplant itself is approximately $330,000.5
Calculations estimate that the cost of treating patients for chronic kidney disease in the
US will likely reach $48 billion per year. To treat just one person with dialysis in the
United States it costs over $50,000.6 In the United States it is estimated that over $40
billion was spent in 2009 for the treatment of patients with kidney disease.7 These costs
are only expected to rise higher. Kidney failure patient care accounts for 6.7% of
Medicare’s total budget, which translates to less than 1% of the covered population.1
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Progression into chronic kidney disease is attributed to two other health
conditions, diabetes and high blood pressure. Symptoms of chronic kidney disease
include fatigue, decreased appetite, insomnia, edema and dry skin. Treatment options for
patients with chronic kidney disease include hemodialysis, peritoneal dialysis, renal
transplant or medical management with medications such as steroids.
Calcineurin inhibitors are currently the standard of care in renal transplant
patients, however these medications can cause nephrotoxicity due to their non-selective
nature. Nephrotoxicity can lead to decreased renal function and eventual graft failure.
Additionally, calcineurin inhibitors can have a negative effect on other comorbid
conditions such as hypertension, diabetes and dyslipidemia.2 The introduction of
belatacept vs. calcineurin inhibitors is an effort to improve renal function and decreased
cardiovascular risks the two main reasons for transplant failure or death. Belatacept is a
selective costimulation blocker, which is intended to avoid renal and non-renal toxicities
such as those seen with the use of calcineurin inhibitors .2
This paper evaluates three randomized controlled trials (RCT) comparing the use
of belatacept versus calcineurin inhibitors in increasing patient/graft survival 1-year post
transplant.

Objective	
  
The objective of this selective EBM review is to determine whether or not belatacept
improves patient/graft survival 1-year post transplant versus calcineurin inhibitor
regimens.
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Methods	
  
	
  

This paper looks at two randomized controlled trials and one post hoc analysis

randomized controlled trial. The populations studied in these trials included adult renal
transplant patients over the age of 18. The interventions studied where belatacept and
cyclosporine. The outcomes measured where patient and graft survival.
	
  

The author performed searches using PUBMED and Medline databases using key

words belatacept, cyclosporine and renal transplant. All articles where searched in the
English language. Each article was published in a peer-reviewed journal. Articles where
selected based on clinical relevance to the question addressed above. Inclusion criteria
included randomized controlled trials. Exclusion criteria included previous Cochrane
reviews. All of the studies used similar statistics to evaluate outcomes, which included
numbers needed to treat (NNT) and numbers needed to harm (NNH).
Table	
  1	
  –	
  Demographics	
  of	
  included	
  studies	
  
Study

Type #Pts

Rostaing8 RCT
(2011)

173

Rostaing9 Post- 1209
hoc
(2011)
anal
ysis
RCT

Age
Mean
43-45
years

Mean
53
yrs.

Inclusion
criteria
-CNI-based
maintenance
immunosuppres
sion stable
dosing onemonth prior.
-cGFR between
35-75 ml/min
per 1.73m2
-Diabetic
-CNI-based
maintenance
immunosuppres
sion stable
dosing onemonth prior.
-cGFR between

Exclusion Criteria

W/d Interventions

-History or recent,
6
recurrent, or severe
AR in current
allograft or history
of graft loss due to
AR
-Positive T or B
cell cross match, a
C4d-positive biopsy
in current allograft
-History or recent,
n/a
recurrent, or severe
AR in current
allograft or history
of graft loss due to
AR
-Positive T or B
cell cross match, a

Belatacept
regimen 5mg/kg
given IV on
days 1, 15, 29,
43 and 57 and
then every 28
days

-Belatacept
More Intensive
regimen (MI)
-Belatacept
Less Intensive
regimen (LI)
-Cyclosporine
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Vincenti1
0
(2010)

RCT

686

Mean
43

35-75 ml/min
per 1.73m2
->18 years old
receiving a
living donor or
standard
deceased donor
kidney
transplant

C4d-positive biopsy
in current allograft
->60 years old
159
-Donors ≥50 years
old who had at least
two other risk
factors(CVA, HTN,
and serum
creatinine >1.5
mg/dL)

Belatacept MI
0-3 months: 10
mg/kg days 1,5;
weeks
2,4,6,8,10,12
4-6 months: 10
mg/kg weeks
16, 20, 24
7-12 months: 5
mg/kg every 4
weeks
Belatacept LI:
0-1month 10
mg/kg days 1,5;
weeks 2,4
2-3 months 10
mg/kg weeks 8,
12
3-12 months 5
mg/kg every 4
weeks

	
  
Outcome	
  
	
  

All studies measured patient/graft survival, which included rejection, failure,

infection or death.
Results	
  
This review examined two randomized controlled trials and one post hoc analysis
randomized controlled trial comparing the used of belatacept and a calcineurin inhibitor,
such as cyclosporine, as a method of immunosuppression following renal transplantation.
The study utilized adult patients who had received a kidney transplant with the inclusion
criteria cited in Table 1. The data reported in all three studies were dichotomous.
In the Vincenti et al. RCT, 686 patients were used to compare belatacept versus
cyclosporine and were included based on the inclusion criteria listed in Table 1.2
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Exclusion criteria not indicated in Table 1 also included patients who had received any
other non-renal solid organ transplants. This study was conducted at 100 centers
worldwide. Patients were randomly placed into one of three different study groups. The
groups consisted of belatacept low intensity, belatacept high intensity and cyclosporine.
The study was blinded to the dosing of the belatacept but open-label to the drug itself.
This paper will focus on the low intensity (LI) belatacept regimen versus cyclosporine.
The belatacept (LI) dosing regimen is as follows; 0-1 month 10 mg/kg on days 1, 5;
weeks 2, 4 then on months 2-3 10 mg/kg during weeks 8 and 12 then on months 3-12 5
mg/kg every 4 weeks. The cyclosporine regimen is as follows; initial daily dose of 4-10
mg/kg then 0-1 month dose adjusted to 150-300 ng/mL then 2-12 months dose adjusted
to 100-250 ng/mL. There are three primary outcomes that where being measured in this
study, (1) composite patient and graft survival, (2) composite renal impairment endpoint
and (3) incidence of acute rejection. The primary outcome of composite patient and
graft survival will be the focus of this paper. The primary outcomes were analyzed
between the treatment groups using a confidence interval 97.3%, with analysis by intent–
to-treat (ITT). The patients receiving belatacept showed a 97% patient/graft survival
after 12 months and the patients receiving cyclosporine showed 93% patient/graft
survival after 12 months, Table 2. The numbers needed to treat indicate that for every 25
patients treated with Belatacept one more case of graft failure after 12 months will be
prevented compared to patients treated with cyclosporine. Adverse events such as tremors
where noted in 16% of cyclosporine patients and 5% of belatacept patients, Table 3. The
numbers needed to harm indicate that for every 9 patients treated with belatacept 1 fewer
would experience an adverse side effect compared to the control group.
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In the Rostaing et al RCT, 173 patients were used to compare belatacept versus
cyclosporine.8 The patients were randomly allocated to either belatacept or their current
calcineurin inhibitor regimen (cyclosporine or tacrolimus). Belatacept regimen is as
follows; 5 mg/kg infusion on days 1,15, 29, 43 and 57, then every 28 days thereafter.
The cyclosporine regimen was to maintain trough serum concentration levels of 100-250
ng/mL. Patients included in this study must have had a renal transplant 6 months prior to
but no longer than 36 before the enrollment process commenced. Individuals where
excluded if they had a history of graft loss due to acute rejection. The data from this
study was compiled from 34 different centers in various countries such as the Americas,
Europe, Australia and India. The primary outcome measured in this study was the change
in glomerular filtration rate from baseline to month 12. Secondary outcomes included
patient and graft survival. It is this secondary outcome that will be evaluated in this
paper. The data was analyzed with intent-to-treat with a confidence interval of 95%. The
experimental belatacept group resulted in no kidney transplant grafts being lost in the
first 12 months following transplantation. One patient in the control group died due to
complications from a myocardial infarction, but the graft was still functioning at time of
death, Table 2. The numbers needed to treat in this study indicated for every 99 patients
treated with Belatacept one more case of patient/graft survival after 12 months will be
prevented compared to the control. Adverse events where experienced by both the
experimental and control groups of this study. Serious adverse events where noted in
24% of belatacept patients and 19% of cyclosporine patients. The two most common
serious adverse events noted where pyrexia and pyelonephritis, Table 3. The numbers

Burns,	
  Belatacept	
  vs.	
  Calcineurin	
  Inhibitors,	
  7	
  
needed to harm that where calculated show that 20 patients need to be treated for 1
person to experience a serious adverse event.
In the Rostaing et al. post hoc analysis RCT, 1209 patients were used to compare
belatacept versus cyclosporine and were included in the study based on the inclusion
criteria as mentioned in Table 1.9 This paper will examine the effects of belatacept low
intensity versus cyclosporine. Patients where randomly selected to be placed into one of
three different trial groups; belatacept medium-intensity (MI), belatacept low-intensity
(LI) and cyclosporine. This is a post hoc analysis and the dosing regimen has been
discussed above. This paper will focus on the belatacept (LI) versus cyclosporine
regimen. The experimental group of low intensity belatacept showed a 92.8%
patient/graft survival rate after 12 months and the cyclosporine group showed an 80.8%
graft survival rate. As indicated in Table 2 for every 9 patients treated with the
experimental belatacept one case of patient graft failure after 12 months will be
prevented. The total percentage of serious adverse side effects noted where 54.6% for
belatacept and 67.2% for cyclosporine, Table 3. The calculated numbers needed to harm,
Table 3, show that for every 8 patients treated with belatacept 1 case of a serious adverse
event would occur.
	
  
Table	
  2.	
  Results	
  of	
  treatment	
  efficacy	
  
Study	
  
Rostaing	
  
Vincenti	
  
Rostaing	
  
(post-‐hoc)	
  
	
  
	
  

CER	
  
0.99	
  
0.93	
  
0.80	
  

EER	
  
1	
  
0.97	
  
0.92	
  

RRR	
  
0.01	
  
0.04	
  
0.14	
  

ARR	
  
0.01	
  
0.04	
  
0.12	
  

NNT	
  
99	
  
25	
  
9	
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Table	
  3.	
  Results	
  of	
  treatment	
  safety	
  
Study	
  
Rostaing	
  
Vincenti	
  
Rostaing	
  
(post-‐hoc)	
  
	
  

CER	
  
0.19	
  
0.16	
  
0.67	
  

EER	
  
0.24	
  
0.05	
  
0.54	
  

RRR	
  
0.26	
  
-‐0.68	
  
-‐0.18	
  

ARR	
  
0.05	
  
-‐0.11	
  
-‐0.12	
  

NNH	
  
20	
  
-‐9	
  
8	
  

Discussion	
  
Belatacept is an FDA approved immunosuppressant drug used in the prevention
of organ rejection.10 Its use is contraindicated in patients who are Epstein-Barr virus
(EBV) seronegative or if their status is unknown.10 Black box warnings for belatacept
include increased risk for post-transplant lymphoproliferative disorder and its use in liver
transplant patients is not recommended due to an increase in graft loss and death.10 This
drug has not been studied in patients less than 18 years of age.10 A limitation of interest is
the fact that the studies were open-label to the type of drug being used. However, this
open label requirement was necessary to monitor patient’s cyclosporine serum levels.
Therefore, bias towards a particular drug cannot be ruled out.
Conclusion	
  
	
  

	
  This review of belatacept versus calcineurin inhibitors shows inconclusive results

regarding patient/graft survival at 12 months. The numbers needed to treat across the
three studies varies from 9 to 99, while the numbers needed to harm range from -9 to 20.
Therefore, it is unreasonable to state whether belatacept does in fact improve patient graft
survival after 12 months compared to the use of cyclosporine as an immunosuppressant
following renal transplantation. An area for further investigation could be to investigate
why patients treated with belatacept had an increase incidence of post-transplant
lymphoproliferative disorder. According to the University of Iowa Hospital an average
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kidney transplant will last 10-12 years.11 An area of study could be to investigate if
belatacept can increase the average length of graft survival.
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